Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer

doi:10.12998/wjcc.v8.i17.3718

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5786)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-6) series.

Item

Count

PDF

436

WORD

202

HTML

2378

Figures (1-4)

292

Tables (1-6)

211

Sum=3519

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

596

Download

1671

Sum=2267

Sep 6, 2020 (publication date) through Jul 24, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Sep 6, 2020; 8(17): 3718-3729
Published online Sep 6, 2020. doi: 10.12998/wjcc.v8.i17.3718

Table 1 Baseline patients’ characteristics, n (%)

Variable	GA (n = 54)	FOLFIRINOX (n = 47)	P value
Age (yr)	65.7 ± 7.8	64.4 ± 8.4	0.445
Male	39 (72.2)	31 (66.0)	0.501
Body weight (kg)	59.2 ± 9.5	58.5 ± 9.9	0.716
Height (m)	1.65 ± 0.08	1.63 ± 0.07	0.352
Body mass index (kg/m²)	21.9 ± 3.1	22.0 ± 3.5	0.852
Psoas muscle area (cm²)	8.6 ± 2.9	8.3 ± 2.1	0.639
Number of metastasis ≥ 2	48 (88.9)	35 (74.5)	0.060
Liver meta	32 (59.3)	31 (66.0)	0.493
Carcinomatosis peritonei	21 (38.9)	16 (34.0)	0.618
Lung meta	13 (24.1)	8 (17.0)	0.389
Primary tumor site			0.778
Head	25 (46.3)	25 (53.2)
Body	14 (25.9)	8 (17.0)
Tail	15 (27.8)	14 (29.8)
ECOG performance status			0.018^a
0 or 1	48 (88.9)	47 (100)
2	6 (11.1)	0 (0)
Diabetes	22 (40.7)	23 (48.9)	0.414
Hypertension	12 (22.2)	12 (25.5)	0.700
Laboratory findings
White blood cell (/µL)	6465.6 ± 2743.0	9780.0 ± 16931.6	0.159
Platelet (10³/µL)	235.9 ± 122.4	270.1 ±107.7	0.142
Neutrophil/lymphocyte ratio	3.72 ± 2.98	3.0 ± 1.87	0.167
Pletelet/lymphocyte ratio	190.2 ± 120.7	159.5 ± 71.0	0.129
C-related protein (mg/dL)	1.49 ± 2.23	1.29 ± 2.00	0.641
Albumin (g/dL)	3.92 ± 0.46	3.98 ± 0.57	0.552
Total bilirubin (mg/dL)	1.41 ± 3.06	1.42 ± 1.60	0.988
CA 19-9 (U/mL)	12881.3 ± 54407.2	1307.1 ± 2079.1	0.153

^aP < 0.05, mean ± SD. GA: Gemcitabine plus nab-paclitaxel; ECOG: Eastern Cooperative Oncology Group; CA: Carbohydrate antigen.

Table 2 Result of chemotherapy response of each regimen, n (%)

	GA (n = 54)	FOLFIRINOX (n = 47)	P value
Best response			0.216
PR	10 (18.5)	5 (10.6)
SD	35 (64.8)	31 (66.0)
PD	9 (16.7)	11 (23.4)
DCR (PR + SD)	45 (83.3)	36 (76.6)	0.402
Dose reduction	41 (75.9)	32 (68.1)	0.385
Delivery dose (%)	78.9 ± 16.5	87.3 ± 11.6	0.005^b
Total over 80% dose	24 (44.4)	30 (65.2)	0.038^a
Duration of chemotherapy (mo)	2.33 (1.43-3.24)	1.63 (1.19-2.08)	0.005^b
Progression free survival (mo)	6.43 (4.43-8.43)	4.90 (4.44-5.36)	0.058
Overall survival (mo)	10.17 (6.03-14.31)	6.93 (5.32-8.54)	0.008^b
2^nd Chemotherapy	24 (44.4)	19 (40.4)	0.687
TS-1	15 (27.8)	1 (2.1)
Gemcitabine mono	0 (0)	12 (25.5)
GA	0 (0)	5 (10.6)
FOLFIRINOX	3 (5.6)	0 (0)
Onyvide	1 (1.9)	0 (0)
5-FU base	5 (9.3)	1 (2.1)
2^nd chemotherapy PFS (mo)	3.23 (2.55-3.91)	2.70 (1.56-3.84)	0.191

^aP < 0.05,

^bP < 0.01, mean ± SD; median (95%CI). GA: Gemcitabine plus nab-paclitaxel; PR: Partial response; SD: Stable disease; PD: Progression disease; DCR: Disease control rate; TS-1: Tegafur/gimeracil/oteracil; 5-FU: 5-fluorouracil; PFS: Progression-free survival.

Table 3 Result in subgroup analysis (neutrophil/lymphocyte ratio)

	NLR ≥ 3 (n = 43)			NLR < 3 (n = 58)			P value
	GA (n = 24)	FFX (n = 19)	P value	GA (n = 30)	FFX (n = 28)	P value	P value
PFS (mo)	3.83 (3.19-4.47)			7.60 (6.51-8.69)			0.000^b
PFS (mo)	3.40 (2.76-4.04)	4.40 (2.65-6.15)	0.676	8.10 (5.06-11.14)	6.57 (3.38-9.76)	0.008^b
OS (mo)	4.47 (2.80-6.14)			10.87 (9.22-12.52)			0.001^b
OS (mo)	3.87 (2.79-4.95)	5.33 (3.87-6.80)	0.648	12.87 (10.41-15.33)	9.93 (5.91-13.95)	0.002^b

^bP < 0.01, median (95%CI). NLR: Neutrophil/lymphocyte ratio; PFS: Progression free survival; OS: Overall survival; GA: Gemcitabine plus nab-paclitaxel; FFX: FOLFIRINOX.

Table 4 Prognosis according to response of neutrophil/lymphocyte ratio

Before chemotherapy > post chemotherapy	Post chemotherapy NLR < 3n = 62		Post chemotherapy NLR ≥ 3n = 39		P value
Before chemotherapy > post chemotherapy	Low > Low,n = 47	High > Low,n = 15	Low > High,n = 11	High > High,n = 28	P value
PFS, median mo (95%CI)	7.20 (6.07-8.33)		3.47 (2.81-4.13)		0.000^b
PFS, median mo (95%CI)	7.60 (6.42-8.79)	5.63 (3.14-8.12)	5.77 (2.29-9.26)	3.33 (3.16-3.50)	0.000^b
OS, median mo (95%CI)	10.87 (9.16-12.58)		4.47 (3.37-5.57)		0.002^b
OS, median mo (95%CI)	11.4 (9.93-12.87)	8.00 (2.45-13.55)	7.63 (3.10-12.16)	7.40 (4.49-10.31)	0.001^b
GA regimen	24 (51.1)	8 (53.3)	6 (54.5)	16 (57.1)	0.112
DCR	43 (91.5)	14 (93.3)	8 (72.7)	16 (57.1)	0.000^b

^bP < 0.01, median (95%CI). Low, LNR < 3; high, NLR ≥ 3; Post chemotherapy, evaluation at 1^st tumor response of chemotherapy, LNR: Neutrophil/lymphocyte ratio; PFS: Progression free survival; OS: Overall survival; GA: Gemcitabine plus nab-paclitaxel; DCR: Disease control rate.

Table 5 Result in subgroup analysis (Eastern Cooperative Oncology Group)

	ECOG = 0 (n = 52)			ECOG = 1 (n = 43)			ECOG = 2 (n = 6)			P value
	GA (n = 25)	FFX (n = 27)	P value	GA (n = 23)	FFX (n = 20)	P value	GA (n = 6)	FFX (n = 0)	P value	P value
PFS (mo)	6.60 (4.28-8.92)			3.90 (2.46-5.34)			3.27 (0.00-8.12)			0.003^b
PFS (mo)	8.93 (4.64-13.22)	5.43 (4.58-6.28)	0.002^b	3.87 (2.03-5.71)	4.40 (1.84-6.96)	0.511	3.27 (0.00-8.12)	NA	NA
OS (mo)	10.77 (6.26-15.28)			6.27 (4.26-8.28)			4.47 (0.00-14.00)			0.000^b
OS (mo)	16.10 (10.50-21.70)	6.97 (3.53-10.41)	0.000^b	6.10 (3.31-8.89)	6.27 (2.76-9.78)	0.674	4.47 (0.00-14.00)	NA	NA

^bP < 0.01, mean ± SD. NA: Not-availiable; ECOG: Eastern Cooperative Oncology Group; PFS: Progression free survival; OS: Overall survival; GA: Gemcitabine plus nab-paclitaxel; FFX: FOLFIRINOX.

Table 6 Adverse events of each regimen

Adverse events	GA (n = 54), n (%)	FOLFIRINOX (n = 47), n (%)	P value
Admission	18 (33.3)	18 (38.3)	0.608
Thromboembolism	3 (5.6)	9 (19.1)	0.035^a
Neuropathy (Grade 1,2/3,4)	28 (51.9) (11/17)	11 (23.4) (10/1)	0.000^b
Neutropenia (Grade 1,2/3,4)	38 (70.4) (12/26)	35 (74.5) (10/25)	0.496
Thrombocytopenia (Grade 1,2/3,4)	22 (40.7) (13/9)	17 (36.2) (6/11)	0.893
Nausea (Grade 1,2/3,4)	11 (20.4) (9/2)	22 (46.8) (18/4)	0.008^b
Fatigue (Grade 1,2/3,4)	31 (57.4) (19/12)	26 (55.3) (17/9)	0.740
Diarrhea (Grade 1,2/3,4)	10 (18.5) (7/3)	12 (25.5) (7/5)	0.322
Colitis/pneumonia	11 (20.4) (4/7)	13 (27.7) (7/6)	0.616

^aP < 0.05,

^bP < 0.01. GA: Gemcitabine plus nab-paclitaxel.

Citation: Han SY, Kim DU, Seol YM, Kim S, Lee NK, Hong SB, Seo HI. Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer. World J Clin Cases 2020; 8(17): 3718-3729
URL: https://www.wjgnet.com/2307-8960/full/v8/i17/3718.htm
DOI: https://dx.doi.org/10.12998/wjcc.v8.i17.3718